| Old Articles: <Older 7401-7410 Newer> |
|---|
 |
The Motley Fool
May 2, 2011
Arundhati Parmar |
Teva pays $6.8B to buy Cephalon, including Minnesota's CIMA Labs Teva diversifies.   |
The Motley Fool
May 2, 2011
Brian Orelli |
Prostate Cancer Drug Roars Ahead Johnson & Johnson's buy of Cougar paid off, but look in the rear view mirror. |
The Motley Fool
April 30, 2011
Arundhati Parmar |
iPad Makes Medtronic More Than Just Cool Roughly 5,000 Apple iPads being used within Medtronic have kept the world's largest medical device company pretty busy developing apps. |
The Motley Fool
April 30, 2011
Brian Orelli |
No Long-Term Guidance? No Problem! Looking good, Merck. |
The Motley Fool
April 29, 2011
David Williamson |
Johnson & Johnson's Traumatic Purchase Johnson & Johnson agrees to purchase trauma and spine specialist Synthes. |
The Motley Fool
April 29, 2011
Brian Orelli |
Nice Efficacy, Pfizer, But... Safety data is most important at this point. Nothing can stop Pfizer's oral rheumatoid arthritis treatment tofacitinib. |
The Motley Fool
April 29, 2011
Brian Orelli |
Oral Multiple Sclerosis Drugs Heat Up Watch out Novartis and Gilenya. |
The Motley Fool
April 29, 2011
Cindy Johnson |
Regeneron Pharmaceuticals Shares Plunged: What You Need to Know Regeneron Pharmaceuticals dropped 12% in intraday trading today after an analyst at RBC Capital downgraded the stock from outperform to sector perform. |
The Motley Fool
April 29, 2011
Brian Orelli |
Show Us the Money, Drugmakers Drugmakers have cash and they aren't afraid to use it -- on themselves. |
The Motley Fool
April 29, 2011
Arundhati Parmar |
Medtronic Stands to Gain From Likely CMS Reversal on MRI-Safe Pacemakers Is this a big opportunity for Medtronic? |
| <Older 7401-7410 Newer> Return to current articles. |
